Selumetinib in Cancers With BRAF Mutations

Inclusion Criteria

• Ability to understand and willingness to sign a written informed consent document
• Histologically confirmed metastatic or unresectable solid tumor
• Results from tumor tissue analysis that show a glutamic acid-for-valine substitution at amino acid position 600 in the BRAF gene (V600E) or other activating BRAF mutation, as determined by high-throughput genotyping
• Patients may have received any number of prior systemic treatments for their cancer
• At least one measurable site of disease by CT, according to standard RECIST criteria 1.0
• ECOG performance status 0-1
• Absolute neutrophil count > 1500 per cubic mm
• Platelet count > 100, 000 per cubic mm
• Hemoglobin > 9 g/dl
• Serum bilirubin 12 weeks
• Patients with melanoma
• Have received chemotherapy or radiotherapy within 4 weeks prior to entering the study (6 weeks for nitrosoureas or mitomycin C), or a targeted therapy within 2 weeks prior to entering the study
• Have not recovered from adverse events due to agents previously administered (CTCAE v3 grade 1 or baseline)
• Currently receiving other investigational agents
• Known brain metastases, unless treated and stable off of corticosteroids for at least four weeks
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD6244
• Prior treatment with a selective inhibitor of RAF or MEK (e.g., RAF265); (note: prior sorafenib is allowed)
• Uncontrolled intercurrent illness, including but not limited to:
• Clinically significant active infection
• Symptomatic congestive heart failure, unstable angina pectoris, and/or cardiac arrhythmia other than atrial fibrillation
• Psychiatric illness/social situations that would limit compliance with study requirements
• Refractory nausea or vomiting, swallowing disorder, or malabsorption syndrome that would interfere with swallowing or absorbing the study medication
• Pregnant and/or breast-feeding women
• Previous or concurrent malignancy, except for the following circumstances:
• Disease-free for at least three years and deemed by investigator to be at low risk for recurrence of that malignancy
• Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin)
• History of solid organ transplantation or other condition requiring the use of immunosuppressive medications
• Uncontrolled hypertension (systolic BP >= 150 or diastolic BP >= 100 that cannot be controlled with medications)
• A mean left ventricular ejection fraction (LVEF) less than 45%